Skip to main navigation
logo
  • Home
  • Overview
  • News & Events
    • Press Releases
    • Events and Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Financials
    • SEC Filings
    • Annual Reports
    • Quarterly Releases
  • Governance
    • Governance Overview
    • Board of Directors
    • Management
    • Committee Composition
  • IR Resources
    • Email Alerts
    • Contact IR

Press Releases

Press Releases

March 2, 2021
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
February 10, 2021
Athira Pharma Announces Exercise of Underwriters’ Option to Purchase Additional Shares
January 20, 2021
Athira Pharma Announces Pricing of Public Offering of Common Stock
January 19, 2021
Athira Pharma Announces Proposed Public Offering of Common Stock
January 7, 2021
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 14, 2020
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors
December 8, 2020
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
December 1, 2020
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
November 12, 2020
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
November 10, 2020
Athira Pharma to Present at Upcoming November Investor Conferences

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Next page next ›
  • Last page last »
Displaying 81 - 90 of 104
< SIGN UP FOR EMAIL ALERTS
CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

FCOI Policy

Privacy Policy

© Athira Pharma, Inc. All rights reserved.